Genelux Corp(GNLX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.87 | Insider Own | 14.05% | Shs Outstand | 45.1M | Perf Week | 4% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | 7.77% | Insider Trans | -1.32% | Shs Float | 38.9M | Perf Month | -17.46% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.2 | Inst Own | 31.7% | Short Float | 11.94% | Perf Quarter | -30.2% |
| Income | -0.04B | P/S | 9411.5 | EPS this Y | 5.23% | Inst Trans | 0.92% | Short Ratio | 13.08 | Perf Half Y | -24.09% |
| Sales | 0.00B | P/B | 5.82 | EPS next 5Y | 44.13% | ROA | -121.8% | Short Interest | 4.64M | Perf YTD | -52.29% |
| Book/sh | 0.36 | P/C | 5.04 | EPS past 3/5Y | -59.75% -8.4% | ROE | -177.93% | 52W High | -75.63% ($8.53) | Perf Year | -73.87% |
| Cash/sh | 0.41 | P/FCF | - | Sales past 3/5Y | -91.03% - | ROIC | -195.51% | 52W Low | 11.83% ($1.86) | Perf 3Y | -84.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1.31% | Gross Margin | -5925% | Volatility(W/M) | 10.43% 8.41% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 7786.5 | Sales Y/Y TTM | - | Oper. Margin | -455275% | ATR (14) | 0.18 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.39 | EPS Q/Q | -7.23% | Profit Margin | -444950% | RSI (14) | 40.09 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.39 | Sales Q/Q | - | SMA20 | -10.26% ($2.32) | Beta | 0.6 | Target Price | $18.83 |
| Payout | - | Debt/Eq | 0.15 | Earnings | 2026/8/13 | SMA50 | -15.5% ($2.46) | Rel Volume | 0.59 | Prev Close | $2.1 |
| Employees | 26 | LT Debt/Eq | 0.13 | EPS/Sales Surpr. | -6.76% - | SMA200 | -22.81% ($2.69) | Avg Volume(3M) | 0.35M | Price | $2.08 |
| IPO | 2023/1/26 | Option/Short | Yes/Yes | Trades | 694 | Volume | 209,681 | Change | -0.95% |
🧬 Genelux is a clinical-stage biopharmaceutical company developing immuno-oncology therapies based on oncolytic viruses. The company has a platform that modifies vaccinia virus to selectively destroy tumors and trigger an immune response, and it continues to advance research targeting solid tumors, including ovarian cancer.
Over the past 1 year, on the lower side
76% below its 1-year high.
Traded less than usual. That is 59% of its average volume.
GNLX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +5.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $941,150. Peers typically go for $1,010.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -85.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 31.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #364 of 597 in the industry
Based on market cap of $94M.
FAQ
What kind of company is GNLX?
GNLX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GNLX?
The market cap of GNLX is approximately $94M, ranking 4,495 within its sector.
What is the 52-week high and low for GNLX?
GNLX has recorded a 52-week high of $8.53 and a low of $1.86.
